Recent IPO GTXI has seen steady insider buying of late, which is pretty unusual for this period of time. Starting this to see if anyone wants to explore why.
It's actually got a marketed product, Toremifene Citrate, which is currently approved for front line metastatic breast cancer. It's been on the market for years, and GTXI is not worth billions, so I gather it's no great shakes. The same molecule is being developed, perhaps in different formulations and dosages, for conditions related to prostate cancer. The rest of the pipe is early, two SARMS in PI, another molecule preclinical.
This is first pass stuff; I'll get up to speed, but I basically know nothing other than the above. All help appreciated. |
